SCHEMBL14698699

SCHEMBL14698699

O=C(CCCCSc1nc2ccccc2c(=O)n1-c1ccc(F)c(Cl)c1)Nc1ccc2c(c1)CCC2

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.62
▸ KMT2A Q03164 3/20 0.62
▸ KDM4E B2RXH2 1/20 0.54
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ RECQL P46063 1/20 0.48
▸ USP2 O75604 2/20 0.46
▸ POLB P06746 2/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ HTT P42858 1/20 0.45
▸ ALDH1A1 P00352 3/20 0.44
▸ RAF1 P04049 1/20 0.44
▸ BRAF P15056 1/20 0.44
▸ GRK2 P25098 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ CTDSP1 Q9GZU7 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14697221 0.95 MAPT (0.65) MAPTKMT2AKDM4ESMN1; SMN2RECQL
SCHEMBL14698759 0.91 MAPT (0.66) MAPTKMT2AKDM4ESMN1; SMN2RECQL
SCHEMBL14697174 0.90 MAPT (0.77) MAPTKMT2AKDM4ESMN1; SMN2RECQL
SCHEMBL16021381 0.86 MAPT (0.48) MAPTKMT2AKDM4ESMN1; SMN2POLB
SCHEMBL14697171 0.85 MAPT (0.69) MAPTKMT2AKDM4ESMN1; SMN2RECQL
SCHEMBL14698647 0.83 MAPT (0.59) MAPTKMT2ASMN1; SMN2USP2POLB
SCHEMBL14697159 0.83 MAPT (0.72) MAPTKMT2AKDM4ESMN1; SMN2RECQL
SCHEMBL14697084 0.83 MAPT (0.80) MAPTKMT2AKDM4ESMN1; SMN2RECQL
SCHEMBL14697381 0.81 MAPT (0.77) MAPTKMT2AKDM4ESMN1; SMN2RECQL
SCHEMBL14697132 0.81 MAPT (0.81) MAPTKMT2AKDM4ESMN1; SMN2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10611733-B2 Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2020-04-07 — — US disclosed
US-20170144978-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SOUTHERN RESEARCH INSTITUTE 2017-05-25 — — US disclosed
US-20170144978-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SOUTHERN RESEARCH INSTITUTE 2017-05-25 — — US disclosed
US-20170144978-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SOUTHERN RESEARCH INSTITUTE 2017-05-25 — — US disclosed
US-9598402-B2 Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections SOUTHERN RESEARCH INSTITUTE (US) 2017-03-21 — — US disclosed
EP-2744787-B1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SOUTHERN RES INST (US) 2016-11-02 — — EP disclosed
US-20140256753-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2014-09-11 — — US disclosed
EP-2744787-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS Southern Research Institute (US) 2014-06-25 — — EP disclosed
WO-2013025508-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SOUTHERN RESEARCH INSTITUTE (US) 2013-02-21 — — WO disclosed
WO-2013025508-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SOUTHERN RESEARCH INSTITUTE (US) 2013-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256753-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS HAVCR2, EIF2AK2, GLS2 MAPT 1316/4885KMT2A 3419/4885KDM4E 3772/4885
US-20170144978-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS ZC3HAV1, EIF2AK2, GTF3C3 MAPT 1974/4885KMT2A 3065/4885KDM4E 3408/4885
US-10611733-B2 Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections ZC3HAV1, EIF2AK2, GTF3C3 MAPT 1974/4885KMT2A 3065/4885KDM4E 3408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback